PD-1抑制剂,卡瑞丽珠单抗,大疱性类天疱疮," /> PD-1抑制剂,卡瑞丽珠单抗,大疱性类天疱疮,"/> PD-1 inhibitors, camrelizumab, bullous pemphigoid,"/> 卡瑞丽珠长期治疗后发生大疱性类天疱疮一例

中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (6): 422-424.doi: 10.12144/zgmfskin202406422

• 临床研究 • 上一篇    下一篇

卡瑞丽珠长期治疗后发生大疱性类天疱疮一例

郑淳之1,2,张民阔1,2,赛雯雯1,2,曹园园1,2,张朝霞1,2,潘付堂1,2,杨宝琦1,2,刘红1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，济南，250022
  • 出版日期:2024-06-15 发布日期:2024-05-08

Bullous pemphigoid occurred after long-term treatment with camrelizumab in a patient with oesophageal cancer: a case report

ZHENG Chunzhi1,2, ZHANG Minkuo1,2, SAI Wenwen1,2, CAO Yuanyuan1,2, ZHANG Zhaoxia1,2, PAN Futang1,2, YANG Baoqi1,2, LIU Hong1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-06-15 Published:2024-05-08

PDF (PC)

97

摘要： 免疫检查点抑制剂（Immune Checkpoint inhibitors, ICI）为肿瘤的治疗带来了颠覆性的改革，但同时也导致较多免疫相关不良事件（immune-related adverse events, irAE）的发生。其中，大疱性类天疱疮（bullous pemphigoid, BP）是一种罕见的irAE，主要表现为红斑基础上出现水疱，疱壁紧张。本文报道1例发生于卡瑞丽珠长期治疗后的大疱性类天疱疮，并对ICI引起BP的诊断及治疗策略进行总结。

关键词: PD-1抑制剂')">">PD-1抑制剂, 卡瑞丽珠单抗, 大疱性类天疱疮

Abstract: Immune checkpoint inhibitors (ICIs) have brought about a disruptive change in the treatment of tumours, but have also led to a higher incidence of immune-related adverse events (irAEs). Among them, bullous pemphigoid (BP) is a rare irAE, which is mainly manifested by blisters with tense blister based on erythema. In this paper, we report a case of BP occurring after long-term treatment with camerelizumab and summarise the diagnosis and treatment strategy of ICI-induced BP.

Key words: PD-1 inhibitors')">">PD-1 inhibitors, camrelizumab, bullous pemphigoid